Sex-based clinical and immunological differences in COVID-19

Kening Li, Bin Huang, Yun Cai, Zhihua Wang, Li Lu, Lingxiang Wu, Mengyan Zhu, Jie Li, Ziyu Wang, Min Wu, Wanlin Li, Wei Wu, Lishen Zhang, Xinyi Xia, Shukui Wang, Qianghu WangmedRxiv 2020 · DOI

Abstract

While epidemiological data early in the pandemic suggested that men were more susceptible to severe COVID-19, the underlying biological mechanisms remained poorly understood. This study analyzes a cohort of 3,057 patients to identify sex-based differences in clinical outcomes, immune cell populations, and antibody kinetics. We find that males face approximately double the risk of mortality and ICU admission, driven by a significantly delayed humoral immune response and a higher propensity for hyper-inflammation. These findings suggest that sex is an independent prognostic factor and highlight the need for sex-stratified clinical management.

Introduction

The COVID-19 pandemic highlighted a consistent global trend: male patients often experience more severe disease courses and higher mortality rates than female patients. Despite this, clinical management and therapeutic trials have largely overlooked sex as a critical biological variable. This research aims to bridge that gap by providing a comprehensive, unbiased comparative analysis of clinical outcomes and immunological profiles between 1,558 male and 1,499 female patients from a single center.

Methodology

The study utilized a retrospective design, analyzing patients admitted to Wuhan Huoshenshan Hospital between February and March 2020. The researchers employed several key techniques to profile the patient cohort:

  • Cellular Immunity Profiling: Flow cytometry was used to quantify peripheral lymphocyte subsets, including B cells, CD4+ T cells, CD8+ T cells, and Natural Killer (NK) cells.
  • Humoral Immunity Tracking: Chemiluminescence assays measured the dynamic levels of SARS-CoV-2 specific antibodies (IgG and IgM) targeting the Spike (S) protein, Receptor Binding Domain (RBD), and Nucleoprotein (N).
  • Statistical Modeling: Multivariable Cox proportional hazards models and Kaplan-Meier survival analysis were used to determine if sex serves as an independent prognostic factor after adjusting for age and comorbidities.

Clinical Outcomes and Risk Assessment

The clinical data revealed a stark contrast between the sexes. Mortality rates for males were more than double those of females (3.0% vs. 1.4%, P=0.004), and ICU admission rates followed a similar pattern (4.7% vs. 2.7%, P=0.005). Survival analysis confirmed that sex is an independent prognostic factor for COVID-19, with a Hazard Ratio (HR) of 2.2 (P=0.003).

Furthermore, male patients exhibited higher rates of multi-organ involvement. COVID-19-induced renal abnormalities were observed in 6.5% of males compared to 4.2% of females, while hepatic abnormalities were significantly more prevalent in men (40.9% vs. 31.7%). These disparities remained significant even when accounting for the fact that the male cohort had higher baseline rates of COPD and liver disease.

The "Indolent" Male Immune Response

A central finding of this study is the disparity in the timing and strength of the adaptive immune response. Females demonstrated a more robust humoral defense, characterized by higher percentages of CD19+ B cells and CD4+ T cells during hospitalization.

Perhaps most importantly, the study identified a significant lag in antibody production among males. In female patients, protective IgG antibodies reached peak levels by the fourth week after symptom onset. Conversely, male patients exhibited an "indolent" (sluggish) response; their RBD-specific IgG levels at week four were significantly lower (11.3 AU/ML) compared to females (34.3 AU/ML). Males did not reach peak antibody levels until approximately the seventh week, leaving a longer window for viral replication and tissue damage.

Inflammation and the Cytokine Storm

Because the male adaptive immune response is delayed, the body may rely more heavily on innate inflammatory responses, which can become pathological. The study found that males had significantly higher baseline levels of C-reactive protein and Interleukin-6 (IL-6). Specifically, 12.0% of male patients experienced IL-6 spikes exceeding five times the normal limit, compared to only 7.1% of females. This hyper-inflammation is a primary driver of the "cytokine storm," leading to acute respiratory distress syndrome (ARDS) and systemic organ failure.

Conclusion and Clinical Implications

The unfavorable prognosis observed in male COVID-19 patients is likely a consequence of weak humoral immunity and a sluggish antibody response. These findings suggest that a "one-size-fits-all" approach to COVID-19 treatment is insufficient.

The authors advocate for several sex-specific clinical considerations:

  1. Early Intervention: Close monitoring and early medical intervention are particularly vital for male patients to prevent the progression to hyper-inflammation.
  2. Targeted Therapies: Men may benefit from early convalescent plasma therapy to provide the antibodies their bodies are slow to produce, effectively bridging the "antibody gap."
  3. Hormonal Research: Investigating the role of estrogen compounds or other hormonal therapies to boost immune responses in males could provide a new avenue for treatment.

While this retrospective study is limited by its single-center design, it underscores the necessity of sex-stratified clinical trials to ensure that therapeutic interventions are optimized for the biological realities of all patients.

Summary updated

Abstract

Abstract Background Males and females differ in their immunological responses to foreign pathogens. However, most of the current COVID-19 clinical practices and trials do not take sex as consideration. Methods We performed an unbiased sex-based comparative analysis for the clinical outcomes, peripheral immune cells, and SARS-CoV-2 specific antibody levels of 1,558 males and 1,499 females COVID-19 patients from a single center. The lymphocyte subgroups were measured by Flow cytometry. Total antibody, Spike protein (S)-, receptor binding domain (RBD)-, and nucleoprotein (N)-specific IgM and IgG levels were measured by chemiluminescence. Results We found that the mortality and ICU admission rates were approximately 2-fold higher in males than that in females (P<0.005). Survival analysis revealed that sex is an independent prognostic factor for COVID-19 (Hazard ratio=2.2, P=0.003). The concentration of inflammatory factors in peripheral blood was significantly higher in males. Besides, the renal and hepatic abnormality induced by COVID-19 was more common in males during the hospitalization. The analysis of lymphocyte subsets revealed that the percentage of CD19+ B cell and CD4+ T cell was significantly higher in females (P<0.001) during hospitalization, indicating the stronger humoral immunity in females than males. Notably, the protective IgG sharply increased and reached a peak in the fourth week after symptom onset in females, while gradually increased and reached a peak in the seventh week in males. Conclusions The unfavorable prognosis of male COVID-19 patients may result from the weak humoral immunity and indolent antibody responses during SARS-CoV-2 infection and recovery. Early medical intervention and close monitoring are important, especially for male COVID-19 patients. Hormonal or convalescent plasma therapy may help improve the immunity of males to fight against SARS-CoV-2 infection.
BibTeX
@misc{li2020sex,
  author = {Kening Li and Bin Huang and Yun Cai and Zhihua Wang and Li Lu and Lingxiang Wu and Mengyan Zhu and Jie Li and Ziyu Wang and Min Wu and Wanlin Li and Wei Wu and Lishen Zhang and Xinyi Xia and Shukui Wang and Qianghu Wang},
  title = {{Sex-based clinical and immunological differences in COVID-19}},
  year = {2020},
  doi = {10.1101/2020.08.29.20126201},
  howpublished = {medRxiv},
}
Figure